JP2021535935A - ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用 - Google Patents

ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用 Download PDF

Info

Publication number
JP2021535935A
JP2021535935A JP2021547984A JP2021547984A JP2021535935A JP 2021535935 A JP2021535935 A JP 2021535935A JP 2021547984 A JP2021547984 A JP 2021547984A JP 2021547984 A JP2021547984 A JP 2021547984A JP 2021535935 A JP2021535935 A JP 2021535935A
Authority
JP
Japan
Prior art keywords
powder according
cannabinoid
powder
maltodextrin
pluronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535935A5 (https=
JPWO2020035850A5 (https=
Inventor
マグダッシ，シュロモ
ラルシュ，リラズ
エズラ，ラファエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karnak Technologies LLC
Original Assignee
Karnak Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karnak Technologies LLC filed Critical Karnak Technologies LLC
Publication of JP2021535935A publication Critical patent/JP2021535935A/ja
Publication of JP2021535935A5 publication Critical patent/JP2021535935A5/ja
Publication of JPWO2020035850A5 publication Critical patent/JPWO2020035850A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547984A 2018-08-13 2019-03-11 ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用 Pending JP2021535935A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL261132 2018-08-13
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (3)

Publication Number Publication Date
JP2021535935A true JP2021535935A (ja) 2021-12-23
JP2021535935A5 JP2021535935A5 (https=) 2022-01-25
JPWO2020035850A5 JPWO2020035850A5 (https=) 2022-01-25

Family

ID=63998426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547984A Pending JP2021535935A (ja) 2018-08-13 2019-03-11 ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用

Country Status (9)

Country Link
US (2) US11712430B2 (https=)
EP (1) EP3716946A1 (https=)
JP (1) JP2021535935A (https=)
CN (1) CN113473965A (https=)
AU (1) AU2019322212B2 (https=)
BR (1) BR112021009869A2 (https=)
CO (1) CO2021007647A2 (https=)
IL (2) IL261132A (https=)
WO (1) WO2020035850A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138630A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
CN114245739A (zh) * 2019-08-12 2022-03-25 腾思凯真私人有限公司 大麻二酚口腔崩解片
KR20230047095A (ko) 2020-07-29 2023-04-06 카낙 테크놀로지스, 엘엘씨 치료용 친유성 활성물질의 개선된 전달을 위한 약제학적 조성물
KR20220128405A (ko) * 2020-07-29 2022-09-20 카낙 테크놀로지스, 엘엘씨 화장용 사용을 위한 친지성 물질의 개선된 포뮬레이션
IL293086A (en) 2020-07-29 2022-07-01 Karnak Tech Llc Formulations of orally administered lipophilic dietary supplements and beneficial oils
CA3188864A1 (en) * 2020-08-14 2022-02-17 Ori LIEBERMAN Dosing capsule made from cannabis-derived resin and methods of making the same
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
AU2024305502A1 (en) 2023-06-16 2026-01-08 Pico Ip, Llc A process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
WO2026037496A1 (en) * 2024-08-14 2026-02-19 Tetra Pharm Technologies A self-emulsifying solid composition comprising a cannabinoid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
WO2017045053A1 (pt) * 2015-09-18 2017-03-23 Prati, Donaduzzi & Cia Ltda Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
WO2018115962A1 (en) * 2016-12-20 2018-06-28 Tilray Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
JP6247685B2 (ja) 2012-05-16 2017-12-13 メワ・シン 実質的に水不溶性の薬物の送達のための医薬組成物
WO2015171445A1 (en) 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
WO2016147186A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
AU2016347651A1 (en) * 2015-10-26 2018-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Novel cannabinoid formulations
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク．Ｓｒｅ Ｗｅｌｌｎｅｓｓ Ｉｎｃ． 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518097A (ja) * 2010-01-26 2013-05-20 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー 肺高血圧を予防および治療するための組成物および方法
JP2018516281A (ja) * 2015-05-28 2018-06-21 インシス・ディベロップメント・カンパニー・インコーポレイテッド 安定なカンナビノイド製剤
WO2017045053A1 (pt) * 2015-09-18 2017-03-23 Prati, Donaduzzi & Cia Ltda Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
WO2018115962A1 (en) * 2016-12-20 2018-06-28 Tilray Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DURAN-LOBATO, M., ET AL., JOURNAL OF NANOPARTICLE RESEARCH, vol. Vol.17, Issue 2, Article ID: 61, JPN6022045906, 2015, pages 1 - 17, ISSN: 0005193994 *
MARTIN-BANDERAS, L., ET AL., COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 123, JPN6022045904, 2014, pages 114 - 122, ISSN: 0005193993 *

Also Published As

Publication number Publication date
US11712430B2 (en) 2023-08-01
CO2021007647A2 (es) 2021-08-30
CA3086887A1 (en) 2020-02-20
AU2019322212B2 (en) 2022-09-29
AU2019322212A1 (en) 2021-04-08
IL275430A (en) 2020-08-31
CN113473965A (zh) 2021-10-01
EP3716946A1 (en) 2020-10-07
IL261132A (en) 2018-11-04
US20210059975A1 (en) 2021-03-04
BR112021009869A2 (pt) 2022-05-17
US20230321031A1 (en) 2023-10-12
WO2020035850A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
JP2021535935A (ja) ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用
US11654111B2 (en) Oral solid cannabinoid formulations, methods for producing and using thereof
US11590230B2 (en) Compositions of therapeutic substances, methods and uses thereof
CN112915121A (zh) 一种大麻素纳米胶束制剂及其制备方法
WO2020146478A1 (en) Cannabinoid formulations for treating alcohol hangover
EP4405047B1 (en) Cannabinoid formulation for oral administration
AU2021317263B2 (en) Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
Alshawwa et al. Solid lipid Lyo-Nanosuspension: a promising stabilized oral delivery system for the antihyperglycemic extract of mistletoe Plicosepalus acacia
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
US20220193008A1 (en) Bioaccessibile compositions of lipophilic compounds and process thereof
KR20080007309A (ko) 신규의 활성 성분 전달용 갈렌계, 제조 방법 및 용도
Javed et al. Patented bioavailability enhancement techniques of silymarin
CA3086887C (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
CA3005885A1 (en) Sustained release cannabinoid pellets
HK40053715A (en) Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
SI26054A (sl) Supernasičljiv brez olja samo-nanoemulgirni sistem za dovajanje zdravil - SNEDDS za v vodi slabo topne farmacevtske sestavine in postopek njegove priprave

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231013

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231117